Solution reagent kit μCaler EMS Panel v1.0

for methylation

μCaler EMS Panel v1.0 (Early Methylation for Screening) covers methylation gene sites related to nine major high-incidence cancers, including selected sites approved by the NMPA and FDA, as well as those reported in literature and patents. It encompasses nine types of cancers, including lung cancer, colorectal cancer, gastric cancer, liver cancer, breast cancer, carcinoma cancer, prostate cancer, cervical cancer, and ovarian cancer, involving 76 methylated candidate genes associated with carcinog enesis and tumor suppression, with over 2,000 CpG sites. The probe design covers approximately 20 Kb of the human genome, providing comprehensive and accurate support for methylation early screening. Product Features Multi-Cancer Detection: Covers CpG sites of multiple genes for 9 major cancer types in a single detection Sample Compatibility: Suitable for gDNA, cfDNA, and various level of FFPE samples. Accurate Quantification: Achieves precise quantification of methylation levels in tested samples. Efficient Capture: Combines with μCaler Total Solution for Methylation to ensure uniform data quality, higher capture eff iciency and stability High Reliability: Utilizes exclusive patented probe design to comprehensively detect methylation status, providing reliable results. Stable Delivery: In-house nucleic acid synthesis manufacturing ensures on-hand delivery and guarantees the stability of the delivery chain. Flexible Customization: Customizes panels containing different genes and scales of CpG sites for testing specific single/ multiple cancer types.